We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

2 hedge funds and large institutions have $119K invested in Scinai Immunotherapeutics in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $118K → $119K (+$1K)

0% less ownership

Funds ownership: 0.18% → 0.18% (-0%)

33% less funds holding

Funds holding: 3 → 2 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.64K

SCNI Hedge Fund Activity: Q3 2016 in Review

2 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2016, worth a combined $119K — up 0.85% from $118K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SCNI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was UBS Group, exiting entirely with an estimated $3.64K sold.

  • 2 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2016, down from 3 in Q2 2016.
  • Funds reported $119K of Scinai Immunotherapeutics stock for Q3 2016, up 0.85% quarter-over-quarter.
  • 0 funds opened new Scinai Immunotherapeutics positions in Q3 2016 and 1 closed out, a net change of -1 holder.
  • The largest Scinai Immunotherapeutics seller in Q3 2016 was UBS Group, an estimated $3.64K sold.

Based on aggregated 13F filings for Q3 2016.